Search

Displaying results 4611 - 4620 of 10000 in total
  1. Drug

    Trilostane

    go.drugbank.com/drugs/DB01108
    ApprovedVet approvedWithdrawn

    Trilostane is an inhibitor of 3 beta-hydroxysteroid dehydrogenase used in the treatment of Cushing's syndrome. It was withdrawn from the United States market in April 1994.

    Categories: Corticosteroids for Systemic Use
  2. Drug

    GT 389-255

    go.drugbank.com/drugs/DB05894
    Experimental

    Peptimmune’s lead product GT 389-255, is a novel lipase inhibitor and fat binding hydrogel polymer conjugate for the treatment of obesity which has completed single and multiple ascending dose (SAD and … It is expected to block fat absorption with fewer side effects than currently marketed lipase inhibitors.

  3. Drug

    Lunacalcipol

    go.drugbank.com/drugs/DB05024
    Investigational

    This proprietary new drug is both a potent inhibitor of CYP24 (the enzyme responsible for the breakdown of vitamin D) and a potent activator of vitamin D signaling pathways. … secretion which may be involved in the etiology of psoriasis.

  4. Drug

    DOTMP HO-166

    go.drugbank.com/drugs/DB05380
    Experimental

    SRT is designed to be used in combination with high-dose chemotherapy producing a direct therapeutic effect on the tumor sites in the bone plus a general bone-marrow effect to destroy myeloma cells in … DOTMP HO-166 is used in skeletal targeted radiotherapy (STR).

    Synonyms: Holmium Ho-166 DOTMP
  5. Drug

    Vapreotide

    go.drugbank.com/drugs/DB04894
    Investigational

    Vapreotide is a synthetic octapeptide somatostatin analog. It was being studied for the treatment of cancer.

    International brands: Sanvar IR
  6. Drug

    Hydrocortisone probutate

    go.drugbank.com/drugs/DB14543
    ApprovedVet approved

    Categories: Corticosteroids, Moderately Potent (Group II)
  7. Drug

    Cediranib

    go.drugbank.com/drugs/DB04849
    Investigational

    It is being developed clinically as a once-daily oral therapy for the treatment of cancer. … The novel indole-ether quinazoline Cediranib is a highly potent (IC<sub>50</sub> &lt; 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro.

  8. Drug

    TRGFT-201

    go.drugbank.com/drugs/DB23064
    ApprovedInvestigational

    [L64070,L64071] Orca-T was approved by the FDA on June 30, 2026 for use in matched-donor hematopoietic stem cell transplantation with a myeloablative preparative regimen, for hematopoietic and immunologic … Orca-T (allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq) is a donor-derived allogeneic cell therapy used in matched-donor hematopoietic stem cell transplantation for adults with blood

  9. Drug

    AEF0117

    go.drugbank.com/drugs/DB27675
    Investigational

    AEF0117 is a small molecule drug. AEF0117 is under investigation in clinical trial NCT05554926 (Study of [4-14C] AEF0117 Following a Single Oral Dose in Healthy Male Subjects).

    Synonyms: 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one, 3β-(4-methoxybenzyloxy)pregn-5-en-20-one
  10. Drug

    NNZ-2591

    go.drugbank.com/drugs/DB15601
    Investigational

    [L11106] It is currently under development by Neuren Pharmaceuticals for the symptomatic treatment of Angelman, Phelan-McDermid, and Pitt Hopkins Syndromes. … [L11100] Clinical trials are expected to begin in 2020.[L11103,L11100]